---
title: Hepatorenal syndrome  HRS 
---
# Hepatorenal syndrome (HRS)
## Reference
* Hepatology 2021;74:1014 
* Gastro 2016;150:1525
* AJKD 2013;62:1198

## Pathophysiology: 
splanchnic vasodilation and renal vasoconstriction w/ â†“ renal blood flow

## [[Criteria-Hepatorenal syndrome (HRS)]]: 
* HRS-AKI: development in <2 wk; usually occurs in severe liver failure, often following precipitating event (see later); median survival 2 wk
* HRS-CKD: more indolent, median survival 6 mo; liver failure present <than in HRS-AKI

## Precipitants: 
GIB, overdiuresis, infection, serial LVP, drugs (aminoglycosides, NSAIDs)

## [[Treatment-Hepatorenal syndrome (HRS)]](see more detail) 
* Albumin + either IV vasopressors (norepi, terlipressin) or octreotide & midodrine

## Reference
[Acute Kidney Injury in Patients with Liver Disease | American Society of Nephrology](https://cjasn.asnjournals.org/content/early/2022/07/28/CJN.03040322?fbclid=IwAR3wjlsaXoAD3CzQ50Ss0VXKkvUnWi4PgyR4u-2NQqqZZj2n1XfSNJJab8g)
